Trelstar (Triptorelin Pamoate) Patent Expiration, LOE Window & CMS Spending
Trelstar (Triptorelin Pamoate) by Verity: FDA Orange Book LOE 2029-06-30, 0 AB generics, $16.7M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Verity |
| FDA Application & Pathway | N020715 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2029-06-30 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $16.7M |
| 2024 Medicare Part D Spend | $15.3M |
| 2024 Medicaid Spend | $1.4M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 18.0% 2-yr change) |